February 12, 2026
Experts redefine trial design for biochemically recurrent prostate cancer, emphasizing PSMA PET nuances, de-escalation, and novel endpoints.
December 11, 2025
Experts establish consensus endpoints for bladder-sparing trials in MIBC, focusing on clinical complete response and robust event-free survival.
December 9, 2025
Pirtobrutinib shows promise as a new upfront treatment for CLL in two Phase 3 trials, demonstrating superiority and a strong safety profile.
December 7, 2025
A new staging system for AL Amyloidosis adds longitudinal strain to identify ultra-high-risk Stage 3C patients, reshaping modern prognosis.
November 24, 2025
The PACIFIC-2 trial failed to improve survival by adding durvalumab simultaneously with chemoradiation in stage III NSCLC. What's next?
November 20, 2025
Childhood cancer survivors over 50 face a 3x higher mortality risk, driven by secondary cancers and chronic conditions from past treatments.
November 13, 2025
5-year Cartitude-1 data shows one-third of RRMM patients remain progression-free after cilta-cel, sparking debate on a potential cure.
October 27, 2025
The Phase III TRILINX trial failed, showing the addition of Xevinapant to chemoradiation worsened outcomes in head and neck cancer.
October 9, 2025
Adolescent and young adult (AYA) cancer survivors face significant, long-term income loss, with some groups never fully recovering financially.
